Varespladib methyl (BioDeep_00000184913)

   

human metabolite blood metabolite


代谢物信息卡片


methyl 2-{[1-benzyl-3-(carbamoylcarbonyl)-2-ethyl-1H-indol-4-yl]oxy}acetate

化学式: C22H22N2O5 (394.1528642)
中文名称:
谱图信息: 最多检出来源 Mus musculus(blood) 50%

分子结构信息

SMILES: CCC1=C(C(=O)C(N)=O)C2=C(OCC(=O)OC)C=CC=C2N1CC1=CC=CC=C1
InChI: InChI=1S/C22H22N2O5/c1-3-15-20(21(26)22(23)27)19-16(24(15)12-14-8-5-4-6-9-14)10-7-11-17(19)29-13-18(25)28-2/h4-11H,3,12-13H2,1-2H3,(H2,23,27)

描述信息

C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic
D004791 - Enzyme Inhibitors > D064801 - Phospholipase A2 Inhibitors
C471 - Enzyme Inhibitor
Varespladib methyl (A-002; LY333013) is a selective inhibitor of group II secretory phospholipase A2 (PLA2).

同义名列表

7 个代谢物同义名

methyl 2-{[1-benzyl-3-(carbamoylcarbonyl)-2-ethyl-1H-indol-4-yl]oxy}acetate; methyl {[1-benzyl-3-(carbamoylcarbonyl)-2-ethylindol-4-yl]oxy}acetate; S-3013VARESPLADIB methyl; Varespladib methyl; a-002LY333013; A-002; LY333013



数据库引用编号

9 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Varnavas D Mouchlis, Aaron Armando, Edward A Dennis. Substrate-Specific Inhibition Constants for Phospholipase A2 Acting on Unique Phospholipid Substrates in Mixed Micelles and Membranes Using Lipidomics. Journal of medicinal chemistry. 2019 02; 62(4):1999-2007. doi: 10.1021/acs.jmedchem.8b01568. [PMID: 30615445]
  • Stephen J Nicholls, Matthew A Cavender, John J P Kastelein, Gregory Schwartz, David D Waters, Robert S Rosenson, Dianna Bash, Colin Hislop. Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial. Cardiovascular drugs and therapy. 2012 Feb; 26(1):71-5. doi: 10.1007/s10557-011-6358-9. [PMID: 22109255]
  • Robert S Rosenson, Heather Fraser, Michael A Goulder, Colin Hislop. Anti-inflammatory effects of varespladib methyl in diabetic patients with acute coronary syndrome. Cardiovascular drugs and therapy. 2011 Dec; 25(6):539-44. doi: 10.1007/s10557-011-6344-2. [PMID: 21989792]
  • Robert S Rosenson, Michael Elliott, Yuri Stasiv, Colin Hislop. Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease. European heart journal. 2011 Apr; 32(8):999-1005. doi: 10.1093/eurheartj/ehq374. [PMID: 21081550]
  • Robert S Rosenson, Heather Fraser, Joaquim Trias, Colin Hislop. Varespladib methyl in cardiovascular disease. Expert opinion on investigational drugs. 2010 Oct; 19(10):1245-55. doi: 10.1517/13543784.2010.517193. [PMID: 20809869]
  • Maung-Maung Thwin, Eleni Douni, Pachiappan Arjunan, George Kollias, Prem V Kumar, Ponnampalam Gopalakrishnakone. Suppressive effect of secretory phospholipase A2 inhibitory peptide on interleukin-1beta-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts, and its antiarthritic activity in hTNFtg mice. Arthritis research & therapy. 2009; 11(5):R138. doi: 10.1186/ar2810. [PMID: 19765281]